The Watchman procedure is a minimally invasive heart procedure that implants a small device inside your heart to reduce stroke risk if you have atrial fibrillation (AFib). It works by sealing off a small pouch in the heart called the left atrial appendage, where dangerous blood clots tend to form. For many patients, the procedure eventually eliminates the need for long-term blood thinners.
Why the Left Atrial Appendage Matters
When your heart beats irregularly due to AFib, blood can pool and form clots. The left atrial appendage, a small finger-shaped pouch in the upper left chamber of the heart, is where the vast majority of these clots originate. If a clot escapes and travels to the brain, it causes a stroke. Blood-thinning medications like warfarin prevent these clots from forming, but they come with their own risks, particularly serious bleeding. Some people experience frequent nosebleeds, bruising, or gastrointestinal bleeding. Others face dangerous bleeding risks due to falls, prior hemorrhages, or other medical conditions.
The Watchman device offers an alternative: rather than thinning the blood throughout your entire body, it physically blocks the source where most clots form.
How the Device Works
The Watchman is a small, parachute-shaped implant made from a nickel-titanium alloy (nitinol) that can compress and then spring back to its original shape. It has a self-expanding metal frame with 10 tiny anchors that grip the walls of the appendage, topped with a fabric cap that faces the main chamber of the heart. The device is sized 8 to 20 percent larger than the opening of the appendage so it compresses snugly against the walls and stays firmly in place.
Once implanted, the body begins growing tissue over the device almost immediately. Within the first few days, a layer of protein forms over the fabric surface, sealing any small gaps between the device and the heart wall. By about 45 days, a full layer of the heart’s own cells covers the device surface, essentially making it part of the heart. This is why the 45-day follow-up visit is so important: your doctor checks whether the device is fully sealed before making changes to your medications.
Who Is a Candidate
The Watchman is designed for people who have AFib not caused by a heart valve problem, along with risk factors that put them at elevated stroke risk. Those risk factors include age over 75, high blood pressure, heart failure, diabetes, prior stroke or mini-stroke, and vascular disease. The more risk factors you have, the stronger the case for treatment.
The key requirement is that you have a valid reason for not taking long-term blood thinners. This could be a history of serious bleeding, a high fall risk, a lifestyle or occupation that makes bleeding dangerous, or simply intolerable side effects from anticoagulant medications. Medicare specifically classifies the Watchman as a second-line therapy, meaning it’s covered when long-term blood thinners aren’t a good fit rather than as a first choice for everyone with AFib.
Medicare and Insurance Coverage
Medicare covers the Watchman procedure, but with specific conditions. You need a stroke risk score (called a CHA₂DS₂-VASc score) of 3 or higher, which accounts for factors like age, high blood pressure, diabetes, and prior strokes. You also need to be suitable for short-term blood thinners during the healing period but unable to take them long-term.
Before the procedure is approved, you must have a formal shared decision-making conversation with a physician who is not part of the team performing the implant. This independent doctor reviews the evidence with you using a standardized tool, and the conversation gets documented in your medical record. The procedure itself must be performed at a hospital with an established structural heart disease program, by a cardiologist or surgeon who has completed manufacturer training and performed at least 25 procedures involving the specific catheter technique used. Most private insurers follow similar criteria.
What Happens During the Procedure
The Watchman is implanted under general anesthesia, so you’ll be completely asleep. The entire procedure typically takes about an hour. Your doctor inserts a thin, flexible tube (catheter) through a vein in the groin and threads it up to the heart. To reach the left atrial appendage, the catheter passes through the wall separating the two upper chambers of the heart, a step called a transseptal puncture. The compressed device travels through the catheter, and once positioned inside the appendage, it’s released and expands to fill the space. Imaging with ultrasound (performed through a probe in the esophagus) guides the placement in real time.
There are no chest incisions and no need for a heart-lung machine. After the procedure, you’ll spend one night in the hospital for monitoring and typically go home the following day.
Risks and Complications
The overall complication rate for the Watchman procedure is low, at about 1.9% based on large registry data. The most common complication is a small accumulation of fluid around the heart (pericardial effusion), which occurs in roughly 0.7% of cases and sometimes requires drainage. Bleeding serious enough to need a transfusion occurs in about 0.1% of implants. Stroke during or immediately after the procedure is extremely rare.
One issue doctors monitor for is blood clot formation on the surface of the device itself before the heart tissue has fully grown over it. In the landmark PROTECT AF trial, about 5.6% of patients were found to have a clot on the device during follow-up imaging. This is one reason you remain on blood-thinning medications for a period after implantation and undergo imaging checks.
Recovery and Returning to Normal Activity
Recovery is relatively quick. Most people return to regular activities within a few days. For the first day or two, you should avoid strenuous exercise, heavy lifting, and climbing stairs to let the catheter insertion site in your groin heal. The puncture site may feel sore or slightly bruised for a short time.
The real recovery timeline is about the medication transition. After implantation, you’ll take a blood thinner plus low-dose aspirin for 45 days while the device seals over with tissue. At 45 days, your doctor performs an imaging study to confirm the device is properly seated and sealed. If everything looks good, you typically switch to a combination of aspirin and another anti-clotting medication for a few more months, then transition to aspirin alone. The newer Watchman FLX model has an FDA-approved option to skip the blood thinner entirely during those first 45 days, using dual antiplatelet therapy instead, which is significant for patients who can’t tolerate any blood thinners even short-term.
Long-Term Effectiveness
Over four years of follow-up in the PROTECT AF trial, patients with the Watchman experienced strokes, blood clots, and cardiovascular death at a rate of 2.3 per 100 patient-years, compared to 3.8 per 100 patient-years for patients on warfarin alone. That translates to a 40% relative reduction in these combined events. The benefit was especially clear for bleeding: hemorrhagic stroke (bleeding in the brain) occurred in just 0.6% of Watchman patients versus 3.7% of those on warfarin over the same period.
Longer-term data from a study following patients for up to five years found ischemic stroke rates of 0.7 per 100 patient-years, well below the 4 to 6.7% annual stroke risk predicted by these patients’ risk scores without treatment. Procedural success, meaning the device was implanted and positioned correctly, was 96.1% in that study. Freedom from death at five years was just under 82.5%, which is notable given that these patients were typically elderly with multiple health conditions.
The Newest Device Generation
The Watchman has gone through several design improvements. The current widely used model, the Watchman FLX, improved on the original with better sealing and repositioning capabilities. The newest version, the Watchman FLX Pro, adds a special coating designed to resist clot formation on the device surface and comes in a larger 40 mm size to treat patients whose left atrial appendage anatomy was previously too large for the device. Early case studies with the FLX Pro have shown 100% procedural success, no complications, and same-day discharge for patients. Follow-up imaging at four months showed no significant clot formation on the device.